GlassScriptPhysician profile
William A Nish
NPI 1821097643
$8,018.25
in general payments reported to CMS, 2019-2025
31 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $888 · 2021: $1,093 · 2022: $1,721 · 2023: $1,362 · 2024: $1,738 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,440 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,440.39 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,440.65 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $1,088.42 | 2019-2025 | |
| Glaxosmithkline, LLC. | $811.53 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $595.64 | 2019-2024 | Dupixent |
| Amgen INC. | $548.29 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $435.72 | 2021-2025 | Cuvitru, Takhzyro |
| Teva Pharmaceuticals USA, INC. | $405.20 | 2019-2023 | Airduo Digihaler |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.74 | 2019-2023 | Spiriva Respimat |
| Pfizer INC. | $277.63 | 2019-2024 | |
| Grifols USA, LLC | $264.63 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Biocryst US Sales Co., LLC | $244.50 | 2021-2024 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $207.71 | 2019-2023 | |
| Optinose US, INC. | $203.77 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $188.99 | 2022-2023 | |
| Kaleo, INC. | $134.68 | 2019-2024 | Auvi-Q |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $133.45 | 2022-2023 | |
| Covis Pharma Gmbh | $123.17 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $95.87 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $86.72 | 2025 | Neffy |
| Octapharma USA, INC. | $76.79 | 2020 | |
| Merck Sharp & Dohme LLC | $66.14 | 2021-2023 | |
| Pharming Healthcare, INC. | $46.52 | 2021-2023 | Ruconest |
| Alk-Abello, INC | $44.45 | 2021-2023 | Grastek, Ragwitek, Odactra |
| Mylan Specialty L.P. | $36.15 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $35.56 | 2019 | |
| Adma Biomanufacturing LLC | $26.38 | 2021 | |
| Incyte Corporation | $24.78 | 2022 | |
| Blueprint Medicines Corporation | $19.15 | 2023 | Ayvakit |
| Phadia US INC. | $16.47 | 2023 | Immunocap |
| Eyevance Pharmaceuticals LLC | $14.03 | 2021 | |
| Circassia INC. | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Nish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.